Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + fludarabine + tumor-infiltrating lymphocytes + aldesleukin (Herlev Hospital)
- Development stage
- Phase 2
- Lead developer
- Iovance Biotherapeutics
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
This regimen is an adoptive cell therapy (ACT) protocol consisting of non-myeloablative lymphodepleting chemotherapy followed by the infusion of autologous tumor-infiltrating lymphocytes (TILs) and subsequent interleukin-2 (IL-2) administration. The chemotherapy phase utilizes cyclophosphamide and fludarabine to deplete host lymphocytes, creating a favorable environment for the engraftment and expansion of the infused cells. The TILs are expanded ex vivo from the patient's own tumor tissue and are primarily composed of CD4+ and CD8+ T cells that recognize tumor-associated antigens. Post-infusion, aldesleukin (recombinant IL-2) is administered to promote the survival and proliferation of the transferred T cells in vivo. This specific protocol is being investigated by Inge Marie Svane at Herlev Hospital for the treatment of oral cavity squamous cell carcinoma (OSCC).
- Other names
- cyclophosphamide + fludarabine + T-cell infusion + Interleukin-2TIL therapyAdoptive cell therapy with TILsT-cell Based Immunotherapy for Treatment of Patients Squamous Cell Carcinoma in the Oral Cavity
02
Targets
DNALIG1 (DNA ligase 1)POLA1 (DNA polymerase alpha)DNA-directed primase/polymerase protein (PrimPol)Interleukin-2 receptor beta/gamma and alpha/beta/gamma complexesRNR (Ribonucleotide reductase)pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on cyclophosphamide + fludarabine + tumor-infiltrating lymphocytes + aldesleukin (Herlev Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + fludarabine + tumor-infiltrating lymphocytes + aldesleukin (Herlev Hospital).